



科兴控股生物技术有限公司 SINOVAC BIOTECH LTD.




Outcomes of Clinical Trials using Booster CoronaVac®

Immunogenicity: Boosting 6 m after 2-dose vaccination in adults Neutralizing antibody increased ≥20 times

SINOVAC


Adult phase 1/2 double blinded RCT

Sample size: 262



Pan HX, et al. "Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial "medRxiv (2021)

Immunogenicity: Boosting 6 m after 2-dose vaccination in the elderly SINOVAC Neutralizing antibody increased ≥30 times




- Neutralizing antibody increased rapidly, ≥20 times 7 days after boosting
- Neutralizing antibody maintained 14-28 days after boosting, significant dose-response relationship


Li M, et al. "A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomized, double-blind, placebo-controlled, phase 1/2 clinical triall" medRxiv (2021)

Immunogenicity: Neutralizing antibody increased rapidly, internal data from Sinovac



Interval betwee 2nd and 3rd de (months)		GMT (positivity rate %)	# subjects	GMT (positivity rate %)	# subjects	GMT (positivity rate %)	# cubiacte	GMT (positivity rate %)
7~8	61	4.43 (26.23)	38	70.79 (100)	24	132.47 (100)	57	122.49 (100)
12~13	33	5.09 (33.96)	25	101.42 (96.15)	29	275.16 (100)	40	248.09 (100)






Persistency: GMT 6 moths after 3rd dose higher than the peak after

2nd dose






- Antibody level declined to a low level 6 months after 2nd dose
- Antibody level declined but remained a relatively high level 6 months after the boosting dose

Immunogenicity: (Chile) Sinovac/Pfizer/AZ boosting vaccine, Antibody level increased substantially






Many countries are now implementing booster dose, Turkey progressed fast





Turkey

Half million vaccinated



Indonesia

Start vaccination, About 1,000 vaccinated



Dominica

Start vaccination, 3rd dose mainly Pfizer but will do Sinovac soon



China

Beijing, 3-6 months apart, 576, Vaccinated No SAE



Immune mechanism research of ConoraVac®3rd dose

Chinese Academy of Sciences/Peking University/National Testing Center/Sinovac

Corona Vac® Serological analysis after 3rd dose: better cross




neutralization ability and persistence

(2-dose)


(3-dose)

Control



CoronaVac® after 3rd dose: broader neutralizing antibody spectrum





- Compared to 2 doses of CoronaVac, 3rd dose induced more comprehensive types of neutralizing antibody
- Compared to 2 doses of CoronaVac and early phase of natural infection: the spectrum of neutralizing antibody spectrum by the 3rd dose has changed (the proportion of IV、V、VI RBD antibody increased, broader spectrum) and the higher somatic mutation rates